EcoDrugPlus

Bcl2 Like 10

Ensembl ID : ENSHHUG00000023972
Gene Symbol: BCL2L10
1 Cross references
122 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSHHUG00000036541
Gene Symbol: BCL2L10
1 Cross references
123 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSHHUG00000014158
Gene Symbol: BCL2L10
1 Cross references
125 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSHHUG00000021863
Gene Symbol: BCR
1 Cross references
198 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSHHUG00000052175
Gene Symbol: BCR
1 Cross references
199 Possible Orthologues:

Bruton Tyrosine Kinase

Ensembl ID : ENSHHUG00000031776
Gene Symbol: BTK
1 Cross references
204 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSHHUG00000029138
Gene Symbol: CCR9
1 Cross references
187 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSHHUG00000031814
Gene Symbol: CXCR4
1 Cross references
195 Possible Orthologues:

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSHHUG00000050217
Gene Symbol: CXCR4
1 Cross references
195 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSHHUG00000048407
Gene Symbol: CFTR
1 Cross references
210 Possible Orthologues:

Cf Transmembrane Conductance Regulator

Ensembl ID : ENSHHUG00000038468
Gene Symbol: CFTR
1 Cross references
210 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSHHUG00000043023
Gene Symbol: DNMT1
1 Cross references
71 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).